XLXiaohua Long

Xiaohua Long

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaohua Long has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Hong Lu

    Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, Renji Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

    5 shared publications
  • Xiao Liang

    Division of Gastroenterology and Hepatology Shanghai Institute of Digestive Disease Key Laboratory of Gastroenterology and Hepatology Ministry of Health Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai China

    5 shared publications
  • Lou Yu

    Shanghai, China

    3 shared publications
  • Wenzhong Liu

    Shanghai, China

    3 shared publications
  • David Yates Graham

    Section of Gastroenterology and Hepatology, Department of Medicine Baylor College of Medicine Houston Texas USA

    2 shared publications
  • Qi Chen

    Shanghai, China

    2 shared publications

Latest Publications

  • Lessons learned from upper gastrointestinal endoscopy in asymptomatic Chinese

    by Yu Huang, Huiyi Li, Xiaohua Long, Xiao Liang, Hong Lu

    Background: The Helicobacter pylori (H. pylori) infection‐related diseases, peptic ulcer, and gastric cancer are frequently asymptomatic until the onset of complications. This study aimed to investigate the prevalence of H. pylori, erosive esophagitis, peptic ulcer, and precancerous lesions such as atrophic gastritis, intestinal metaplasia, gastric dysplasia, and upper gastrointestinal (GI) malignancy in asymptomatic Chinese.Methods: From January to December 2017, a questionnaire was administered to consecutive asymptomatic patients undergoing routine physical examination, which included their first screening esophagogastroduodenoscopy. H. pylori infection was determined by one of positive 13C urea breath tests or rapid urease test and histology. The presence of H. pylori infection, erosive esophagitis, peptic ulcer, precancerous gastric histology, and upper GI malignancy was analyzed in relation to demographic factors.Results: A total of 1108 subjects (mean age: 48, range 21 to 79, 39.5% men) were included. The findings were: erosive esophagitis 7.8%, active H. pylori infection 44%, peptic ulcer 9.1% (duodenal 5.8%, gastric 2.5% or both 0.8%); 0.5% had gastric cancer. Male, smoking history, and current H. pylori infection were all significantly related to the presence of peptic ulcer. Totally, 1095 patients had gastric histopathology and premalignant gastric lesions were present in 67.4%; atrophic gastritis (67.4%), intestinal metaplasia (27.4%), and gastric dysplasia (0.5%). Age, current and previous H. pylori infection were risk factors significantly associated with precancerous lesions.Conclusions: Upper GI pathology as a sequelae of H. pylori infection is common in asymptomatic Chinese. These findings support institution of a nationwide test and treat program to eradicate H. pylori in China.


  • Open Access

    High‐dose PPI‐amoxicillin dual therapy with or without bismuth for first‐line Helicobacter pylori therapy: A randomized trial

    by Lou Yu, Laisheng Luo, Xiaohua Long, Xiao Liang, Yingjie Ji, David Y. Graham, Hong Lu

    Background: A reliably highly effective high‐dose proton‐pump inhibitor plus amoxicillin (dual Helicobacter pylori therapy) has remained elusive. We compared whether the addition of bismuth to high‐dose dual therapy would improve the efficacy of high‐dose dual therapy as first‐line treatment.Methods: This was an open‐label, randomized single‐center study of 160 treatment‐naive patients with H. pylori infection who were randomly assigned to 14‐day therapy with esomeprazole 40 mg twice a day plus amoxicillin 1 g three times a day with or without bismuth potassium citrate 600 mg (elemental bismuth 220 mg) twice a day. Antibiotic resistance was determined by agar dilution method and eradication by 13C‐urea breath test.Results: The per‐protocol eradication rates were 96.1%; 95% CI = 88.9%‐99.2% (73/76) without bismuth vs 93.3%; 95% CI = 85.1%‐97.8% (70/75) with bismuth (P = 0.494). The intention‐to‐treat eradication rates were 92.5%; 95% CI = 84.4%‐97.2% (74/80) without bismuth and 88.8%; 95% CI = 79.7%‐94.7% (71/80) with bismuth (P = 0.416). Resistance to amoxicillin, clarithromycin, metronidazole, and levofloxacin was 0%, 31.7%, 81.4%, and 40.7%, respectively. Smoking reduced treatment effectiveness limited to those not receiving bismuth. The per‐protocol eradication rates were 70% (7/10) vs 100% (66/66) in smokers vs non‐smokers without bismuth (P = 0.002), and 100% (10/10) in smokers vs 92.3% (60/65) in non‐smokers with bismuth (P = 1.0). The adverse event rates were 7.5% (6/80) without bismuth vs 11.3% (9/80) with bismuth (P = 0.416).Conclusions: Fourteen‐day high‐dose dual therapy was both effective and safe for first‐line treatment in a region of high prevalence antibiotic resistance. Adding bismuth only improved treatment effectiveness among smokers.


  • Randomised controlled trial: susceptibility‐guided therapy versus empiric bismuth quadruple therapy for first‐line Helicobacter pylori treatment

    by Qi Chen, Xiaohua Long, Yingjie Ji, Xiao Liang, Dongping Li, Hong Gao, Beili Xu, Ming Liu, Ying Chen, Yunwei Sun, et al.

    Summary: Background: Increasing Helicobacter pylori resistance has led to decreases in treatment effectiveness.Aim: To test the effectiveness of susceptibility‐guided therapy vs a locally highly effective empiric modified bismuth quadruple therapy for first‐line H pylori treatment in a region with high antimicrobial resistance.Methods: We compared 14‐day susceptibility‐guided with empiric therapy using a multicentre superiority‐design trial, which randomised H pylori infected subjects 3:1 to (a) susceptibility‐guided therapies contained esomeprazole 20 mg and amoxicillin 1 g b.d. plus clarithromycin 500 mg, metronidazole 400 mg b.d., or levofloxacin 500 mg daily for susceptible infections or bismuth 220 mg b.d. and metronidazole 400 mg q.d.s. for triple‐resistant infections; (b) Empiric therapy contained esomeprazole 20 mg, bismuth 220 mg b.d., amoxicillin 1 g and metronidazole 400 mg t.d.s. Primary outcome was H pylori eradication.Results: Between February 2017 and March 2018, 491 subjects were screened and 382 were randomised. Both the susceptibility‐guided and the empiric regimens were highly successful with per‐protocol eradication rates of 97.7% (250/256) vs 97.6% (81/83, P = 1.00) and intent‐to‐treat eradication rates of 91.6% (262/286) vs 85.4% (82/96, P = 0.12). Overall, susceptibility‐guided therapy was not superior to empiric therapy with 0.1% per‐protocol (95% CI −3.1% to 3.2%) and 6.2% intent‐to‐treat (−0.3% to 12.7%) eradication difference. Both approaches had high adherence and low adverse event rates.Conclusions: Both susceptibility‐guided and empiric therapies provided excellent eradication rates. Clinically, the choice would hinge on availability of susceptibility testing and/or a locally highly effective empiric therapy.


  • Open Access

    Cost‐effectiveness analysis of screen‐and‐treat strategy in asymptomatic Chinese for preventing Helicobacter pylori‐associated diseases

    by Qi Chen, Xiao Liang, Xiaohua Long, Lou Yu, Wenzhong Liu, Hong Lu

    Background: The high prevalence of Helicobacter pylori (H pylori) infection in China results in a substantial public health burden. Medical experts have not agreed on the best solution of population intervention for this problem. We presented a health economic evaluation of a population‐based H pylori screen‐and‐treat strategy for preventing gastric cancer, peptic ulcer disease (PUD), and nonulcer dyspepsia (NUD).Materials and Methods: Decision trees and Markov models were developed to evaluate the cost‐effectiveness of H pylori screening followed by eradication treatment in asymptomatic Chinese. The modeled screen‐and‐treat strategy reduced the risk of gastric cancer, PUD, and NUD. The main outcomes were the costs, effectiveness, and the incremental cost‐effectiveness ratio. Uncertainty was explored by one‐way and probabilistic sensitivity analyses.Results: For preventing gastric cancer, PUD, and NUD together in a cohort of 10 million asymptomatic Chinese at the age of 20 years, the H pylori screen‐and‐treat strategy saved 288.1 million dollars, 28 989 life years, and 111 663 quality‐adjusted life years, and prevented 11 611 gastric cancers, 5422 deaths from gastric cancer, and 1854 deaths from PUD during life expectancy. Uncertainty of screening age from 20 to 60 did not affect the superiority of the screen‐and‐treat strategy over the no‐screen strategy. The one‐way and probabilistic sensitivity analyses confirmed the robustness of our study's results.Conclusions: Compared with the no‐screen strategy, population‐based screen‐and‐treat strategy for H pylori infection proved cheaper and more effective for preventing gastric cancer, PUD, and NUD in Chinese asymptomatic general population.


  • Bismuth improves efficacy of proton‐pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance

    by Xiaohua Long, Qi Chen, Lou Yu, Xiao Liang, Wenzhong Liu, Hong Lu

    Background: Helicobacter pylori (H. pylori) eradication has become increasingly difficult especially for penicillin allergy patients.Aims: To evaluate the efficacy of adding bismuth or high‐dose metronidazole to an H. pylori eradication regimen containing a proton‐pump inhibitor, clarithromycin, and metronidazole in patients allergic to penicillin.Methods: Pilot study in which penicillin‐allergic, treatment‐naive subjects were randomized (1:1) to 14‐day esomeprazole (20 mg q12h), clarithromycin (500 mg q12h), and high dose of metronidazole (400 mg q6h) with (BECM group) or without (ECM group) bismuth (600 mg q12h). Eradication was confirmed by 13C‐urea breath test 6 weeks after therapy. Antimicrobial susceptibility was assessed by the agar dilution method. Adverse events were recorded.Results: Sixty‐six subjects were randomized, four were lost to follow‐up and eight violated the protocol. The eradication rates were 63.6% (95% CI: 47.2%‐80.0%) for ECM vs 84.8% (95% CI 72.6%‐97.1%) (p = .049) for BECM by intention‐to‐treat, 67.7% (95% CI 51.3%‐84.2%) vs 90.3% (95% CI 79.9%‐100%) (p = .029) by modified ITT, and 70% (95% CI 53.6%‐86.4%) vs 96% (95% CI 88.3%‐100%) (P = .033) by per‐protocol. Metronidazole, clarithromycin, and dual‐resistant rates were 74.2%, 24.2%, and 18.2%, respectively. The cure rates were significantly improved by the addition of bismuth for both clarithromycin‐resistant isolates (100% vs 25%, P = .024) and metronidazole‐resistant isolates (94.7% vs 63.6%, P = .043). Adverse events were reported by 45.5% of subjects in ECM group and 48.5% in the BECM group (P = .805).Conclusions: This prospective trial demonstrated that while high‐dose metronidazole could not completely overcome metronidazole resistance, bismuth was additive and improved the overall cure rates by 21%‐26%.